Cogent Biosciences, Inc. (COGT) › Operating IncomeCogent Biosciences, Inc. (COGT) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2017: -$26.15M2018: -$36.01M2019: -$32.18M2020: -$82.20M2021: -$75.55M2022: -$147.84M2023: -$208.13M2024: -$275.94M2025: -$333.36M-$333.36M2017Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$333.36M-20.8%2024-$275.94M-32.6%2023-$208.13M-40.8%2022-$147.84M-95.7%2021-$75.55M+8.1%2020-$82.20M-155.5%2019-$32.18M+10.6%2018-$36.01M-37.7%2017-$26.15M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share